ChromoGenics Q4 2022: Strategic partners and commercialization in focus - Redeye

Redeye provides an update on ChromoGenics following the company's Q4 results. The quarter marked the end of a challenging year for the company, but it is now better equipped than last year as it heads into 2023. Nevertheless, there is still much work to be done in navigating the tough macroeconomic environment for ChromoGenics.

Länk till analysen i sin helhet: https://www.redeye.se/research/880538/chromogenics-q4-2022-strategic-partners-and-commercialization-in-focus?utm_source=finwire&utm_medium=RSS